About Bone morphogenetic protein 10
Bone morphogenetic protein 10 (BMP10) is a protein
from Homo sapiens identified by UniProt accession
O95393, 424 residues long.
MolForge cross-references it against 0 known binders and
216 disease associations.
Target properties
| Protein name | Bone morphogenetic protein 10 |
| UniProt accession | O95393 |
| Gene | BMP10 |
| Organism | Homo sapiens |
| Length | 424 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (216)
Diseases linked to this target (Open Targets).
- hemoglobin measurement · score 0.30
- hematocrit · score 0.29
- colorectal neoplasm · score 0.26
- gut microbiome measurement · score 0.22
- lung adenocarcinoma · score 0.21
- breast adenocarcinoma · score 0.18
- endometrial cancer · score 0.14
- atrial fibrillation · score 0.12
- head and neck squamous cell carcinoma · score 0.11
- monocyte count · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O95393-F1 | alphafold | PREDICTED | 74.04 | — |
Amino-acid sequence (424 residues)
MGSLVLTLCA LFCLAAYLVS GSPIMNLEQS PLEEDMSLFG DVFSEQDGVD FNTLLQSMKD EFLKTLNLSD IPTQDSAKVD PPEYMLELYN KFATDRTSMP SANIIRSFKN EDLFSQPVSF NGLRKYPLLF NVSIPHHEEV IMAELRLYTL VQRDRMIYDG VDRKITIFEV LESKGDNEGE RNMLVLVSGE IYGTNSEWET FDVTDAIRRW QKSGSSTHQL EVHIESKHDE AEDASSGRLE IDTSAQNKHN PLLIVFSDDQ SSDKERKEEL NEMISHEQLP ELDNLGLDSF SSGPGEEALL QMRSNIIYDS TARIRRNAKG NYCKRTPLYI DFKEIGWDSW IIAPPGYEAY ECRGVCNYPL AEHLTPTKHA IIQALVHLKN SQKASKACCV PTKLEPISIL YLDKGVVTYK FKYEGMAVSE CGCR
Explore Bone morphogenetic protein 10 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets